Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. Introduction: There are no currently approved treatments for choroideremia, an X-linked progressive inherited retinal degeneration that leads to blindness by middle age. Several treatment options are being explored, but with major advances in adeno-associated vector (AAV) gene replacement therapy that has reached phase III clinical trials. Areas covered: In this review, we discuss new insights into the clinical phenotyping and genetic testing of choroideremia patients, that aid disease characterization, progression and patient inclusion into clinical trials. Recent advances in in-vitro studies have resulted in the development of functional assays that can be used to confirm the diagnosis in challenging cases and to quantify vector potency for use in clinical trials. We review the progress in current gene therapy trials and some considerations toward gene therapy approval for the treatment of choroideremia. Lastly, we discuss developments in alternative therapies including optogenetics. Expert opinion: AAV gene replacement therapy is the most promising treatment strategy for choroideremia, that has developed exponentially over the last few years with a phase III clinical trial now underway. Optogenetics is a promising alternative strategy that might be applicable in late stages of degeneration.

Original publication

DOI

10.1080/17469899.2019.1699406

Type

Journal article

Journal

Expert Review of Ophthalmology

Publication Date

02/11/2019

Volume

14

Pages

277 - 285